Tag
Generic Pharmaceuticals
2 articles
Alembic Pharmaceuticals Q1 Revenue Up 26% YoY
Alembic Pharmaceuticals reported unaudited Q1 FY27 results with revenue growth of 26% YoY to ₹2,150 Cr.
EBITDA pre R&D increased 21% YoY to ₹523 Cr with margins at 24%, while PAT grew 12% to ₹173 Cr.
Alembic Pharmaceuticals Q1 Revenue Up 26% YoY
Alembic Pharmaceuticals reported 26% YoY revenue growth to ₹2150 Cr in Q1 FY27.
EBITDA pre R&D increased 21% YoY to ₹523 Cr with margins at 24%.
US formulations drove growth with 49% increase, while I